ONUMMIX® is a trademark of CRISPR Biotech Engineering. We are focused to explore the role of biomarkers in immunogenomics. Our interests in immunogenomics research include the evaluation of multiple biomarkers, to design a composite biomarker approach and the creation of computational methods for predicting antigen presentation and TCR binding.
At CRISPR Biotech Engineering (CBE), we are an early-stage genome editing company that is 100% committed to using innovative CRISPR-Cas9 technology to improve human lives, develop transformative gene-based therapies and equip students, scientists and researchers with the knowledge to help them understand how the revolutionary technology can transform human life as we know it.
Do you wish to learn about CRISPR-Cas9 technology? Visit our website at: www.crispr-bte.com
Strategic partnerships are a core component of our chief strategies, empowering us to come up with the resources, knowledge and capabilities to support our research, training and therapeutic programs around immunogenomics.
If you are a biopharma company, university, academic center, or any other organization that has vested interests in immunogenomics, please get in touch with us.